Hepatitis C
304 results
1 - 100
Hepatitis C- MICROBIOLOGY
- CLINICAL
- SITES OF INFECTION
- TREATMENT
- General comments
- Treatment-naive
- Treatment failures
- HIV/HCV co-infection
- Cirrhotic patients
- Chronic kidney disease patients
- Regimens NOT recommended
- Follow-up
- Experimental and Future HCV Treatment Options
- Prevention
- OTHER INFORMATION
- Basis for recommendation
- References
- Hepatitis Due to Infections other than Hepatitis A, B, C, D, or E
Viral Hepatitis- Ribavirin
- Daclatasvir
- Chronic Hepatitis
- Hepatitis B (HBV) vaccines
- Interferon alpha (ABX)
- Hepatitis A
- Sofosbuvir + velpatasvir
INTERFERONS, ALPHA- Hepatitis A vaccine (HAV)
- Staging Liver Disease
- Tipranavir
- interferon alpha-2b
- daclatasvir
- elbasvir/grazoprevir
- Sofosbuvir
- ombitasvir/paritaprevir/ritonavir
- Elbasvir/Grazoprevir
- Hepatitis D
- ombitasvir/paritaprevir/ritonavir/dasabuvir
- peginterferon alfa-2a
- abacavir/dolutegravir/lamivudine
- interferon alfacon-1
- Retroviral Syndrome, Acute
- Technivie
- Telithromycin
- Cirrhosis
- Hepatitis B
- ribavirin
- Simeprevir
- Ticarcillin
- Piperacillin
- Myocarditis
- ruxolitinib (topical)
- Substance Use Disorders
- Ticarcillin + Clavulanic Acid
- Epstein-Barr Virus (Infectious Mononucleosis)
- telaprevir
- COVID-19 Convalescent Plasma
- Sofosbuvir + Ledipasvir
- Opioid Intoxication
- simeprevir